• O1.1 - What is Innovation in Public Health? | Matthew FUNG

• O1.2 - A Toolkit for the Identification and Assessment of New and Emerging Health Technologies | Inaki GUTIERREZ-IBARLUZEA

• O1.3 - Differences in the Identification of New and Emerging Technologies: Analysis of the EuroScan Database | Jose ASUA

• O1.4 - Evaluation Criteria to Assess the Value of Identification Sources for Horizon Scanning | Joanna SMITH

• O1.6 - Sources to be taken into account for the identification of new and emerging health technologies | Gaizka BENGURIA-ARRATE, Inaki GUTIERREZ-IBALUZEA

• O2.1 - The Philippine Health Insurance Corporation’s Experience in the Dissemination and Implementation of Clinical Practice Guidelines
  | Ronal PAGUIRIGAN

• O2.2 - Supporting the Adoption and Implementation of New Technologies into NHS Scotland | Karen RITCHIE

• O2.4 - The Scope and Influence of Rapid HTAs from Members of INAHTA | David HAILEY

• O2.5 - Profile of HTA Users and Applicability of HTA Reports to Inform Decisions in Latin America | Andres PICHON-RIVIERE

• O2.6 - Triangulation of Methods to Assess the Impact of Evidence Reports | Evelyn DORENDORF

• O3.1 - The Effectiveness of Citronella Products against Mosquito Bites: A Systematic Review | Itsarawan SAKUNRAK

• O3.2 - Primary Care Professionals’ Perceptions on Frequent Attendance: Definitions, Motives, Profiles and Relationships with Frequent Patients | Antonio Sarria SANTAMERA

• O3.3 - Identifying Potentially Cost Effective Chronic Care Programs for People with Heart Failure, Diabetes or COPD
  | Lotte MG STEUTEN

• O3.6 - Folic Acid with and without Aspirin in the Chemoprevention of Colorectal Cancer: A Systematic Review
  | Christopher CARROLL

• O4.1 - Beyond Test Accuracy: Data Collection Helps Address Some Uncertainties in Positron Emission Tomography (PET) | Lukas P STAUB

• O4.2 - Mini-HTA: Focused Assessment with Sonography for Trauma (FAST) | Jen Jen OH

• O4.3 - Appropriateness of Diagnostic Imaging Technologies for Acute Abdominal Pain | Juan Antonio BLASCO

• O5.3 - Public perceptions of resource allocation in a Pandemic: A Citizens Citizens’ Jury using Grid/ Group Analysis | Annette BRAUNACK-MAYER

• O5.5 - The Current Capacity and Future Development of Economic Evaluation for Policy Decision Making: A Survey among Researchers and Decision Makers in Thailand | Usa CHAIKLEDKAEW

• O6A.2 - Early to Late Stage HTA in Cooperation with the Industry in the Medical Device Sector | Lotte MG STEUTEN

• O6A.5 - Bridging the gap between aggregate data and individual patient management – a Bayesian approach | Gert Jan Van Der WILT

• O6A.6 - Health Technology Assessment and Pragmatic Controlled Trials
  | Eva Ulrisken DRABORG

• O6B.2 - A Comparison of Health Care Resource Utilisation and Expenditure Among Attention-Deficit Hyperactivity Disorder Subjects Treated with Stimulants versus Nonstimulants | Rahul SASANE

• O6B.4 - Providing Immediate Concurrent Feedback for Antimicrobial Prescription – Can it Decrease Antimicrobial Resistance | Wai Leng CHOW

• O6B.5 - Practical Trial: Cost-Effectiveness Analysis of Intensive Care Post-Discharge Review Clinics | Rodolfo A HERNANDEZ

• O6B.6 - Good Governance in Health Outcomes Research: A Case of Vietnam with Foreign Aid Assistance| Allen LAI

• O7.1   -  Methods of evidence synthesis for Health Technology Assessments (HTA) | Karen RITCHIE

• O7.2 - Questionable Reproducibility of Systematic Reviews: A Case Study on Treatment for Stress Urinary Incontinence | Jennifer HISLOP

• O7.6 - A  Bibliometric Analysis of 100 Most Cited Systematic Review and Meta-Analysis Articles | CHEN Yen-Fu

• O8.5 - Evidence-Based Coverage Decision Making of Genetic Tests: An Experience from the Brazilian Private Health Insurance Sector | Eduardo VIEIRA NETO

• O8.6 - Evaluating “Immature” Technologies: Grading Uncertainty and Informing the Coverage with Evidence Development Option | Antonella NEGRO

• O8.7 - Utility of a Register for Assessment of a New Surgical Procedure | Sally GALLAUGHER

• O9.1 - Rehabilitation of Breast Cancer Patients | Lene Kristine JUVET

• O9.3 - Safety and Efficacy of Human Papillomavirus Vaccines: A Systematic Review and Meta-Analysis | Ana Lopez-POLIN

• O9.4 - The Role of HTA in Priority Setting in Healthcare: A Case Study of the Introduction of HPV-Vaccination in Norway | Anen RINGARD

• O9.5 - Cost-Effectiveness of the THINPREP System for Population Screening in Australian Women | Sarah NORRIS

• O10.1 - A Case Study of the Implementation of an Oncology Information System in Two Hospitals in Sydney | Ping YU

• O10.2 - The Effectiveness of Digital Hearing Aids and Assistive Listening Devices for Adults with Hearing Loss: A Systematic Review of the Literature | Wasan Ihsan ALI

• O10.4 - Cost-effectiveness of Hypothermic Machine Preservation versus Static Cold Storage in Renal Transplantation | Henk GROEN

• O10.5 - Automated Anaesthesia – An Emerging Health Technology: Hope or Hype? | Preethy J Mathew

• O10.6 - Supporting Decision Making When Evidence is Poor: The Use of Class 3b and 4 Lasers and Intense Pulsed Light (IPL) Sources for Cosmetic Purposes in Non-Medical Settings | Sylvie BEAUCHAMP

• O11.2 - A Systematic Review of Cost of Liver Transplantation | Christian S VAN DER HILST

• O11.3 - Which Proton Pump Inhibitors Provide the Greatest Clinical Benefit?
  | Julie BIGA

• O11.6 - Transient Elastography for Diagnosis of Liver Fibrosis: A Systematic Review and Meta-Analysis | Mar POLO

• O12.1 - What is it that policy makers should know about statins? A Bayesian approach to the question of the (in)equivalence of statins | Gert Jan Van Der WILT

• O12.3 - Does Unrecorded Cardiovascular Disease Prevalence Increase with Increasing Deprivation? | Gerrard ABI-AAD

• O12.5- Can We Trust Patient-Reported Outcomes in Health Technology Assessments? A Systematic Review of the Efficacy and Safety of Transmyocardial and Percutaneouslaser Revascularization for Refractory Angina Pectoris | Josie MESSINA

• O12.6 - Appropriateness Explicit Criteria for Carotid Revascularization | Juan Antonio BLASCO

• O13.1 - EUnetHTA Strategy for and Initiatives with Stakeholder Involvement | Marie Louise BISTRUP

• O13.2 - How Should HTA Agencies Use Stakeholders? An Example from the United States | Newell MCELWEE

• O15.2 - A Cost-Effectiveness Analysis of Vitamin D and Calcium Therapy to Reduce Falls and Fall-Related Injuries in Community-Dwelling Elderly Women in Ontario – Results from the Falls/Fractures Economic Model in Ontario Residents (FEMOR) Aged 65 Years and Over | Kiran M CHANDRA

• O15.3 - Effect of Coenzyme Q10 in Neurodegenerative Disorders | Theerapich PAOPENG

• O16.1 - Cost-Utility of Bariatric Surgery in the Treatment for Severe Obesity in Finland | Suvi MAKLIN

• O16.2 - Appropriateness Criteria for Vertebral Anthrodesis: Thoracolumbar, Lumbar and Lumbosacral Spine | Isabel Maria MARTINEZ-FEREZ

• O16.3 - Investigating the Belief that Contact Between Consultant Teams Could Influence the Clustering of Relatively Novel Surgical Procedures: A Cross-Sectional Survey Using Hospital Statistics Data | Mirella MARLOW

• O17.1 - Adaptation of HTA Reports from Different Contexts: Identification of the Need for a Toolkit to Aid the Process | Sheila Margaret TURNER

• O17.2 - Internal Evaluation of EUnetTHA Project 2006 to 2008 (European Network for Health Technology Assessment) – Structure of Evaluation and Overall Results | Lise Lund HAHEIM

• O17.3 - Internal Evaluation of EUnetTHA Project 2006 to 2008 (European Network for Health Technology Assessment). Results of Participant Surveys | Inaki IMAZ Eunethta

• O17.4 - Ranking of Expensive Drugs Based on Cost-Utility Ratios Prior to Coverage Decision-Making on Therapeutic Programs of the National Health Fund in Poland | Krzysztof LANDA